According to our latest study on "Viral Vector Manufacturing Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis - by Type, Disease Indication, Application, End User," the viral vector manufacturing market size was valued at US$ 1.74 billion in 2024 and is expected to reach US$ 5.76 billion by 2031; it is estimated to record a CAGR of 18.8% from 2025 to 2031.

The viral vector manufacturing market is segmented into five major regions-North America, Europe, Asia Pacific (APAC), the Middle East & Africa (MEA), and South & Central America. Asia Pacific dominated the market in 2024, followed by Europe and North America, respectively. Asia Pacific is rapidly emerging as a significant force in viral vector manufacturing, propelled by its expanding biopharmaceutical sector, growing healthcare investments, and increasing focus on advanced therapies. Countries such as China, Japan, South Korea, and India are spearheading efforts to build local manufacturing capabilities, reduce dependency on imports, and foster innovation in gene and cell therapies. In 2025, companies such as Wuxi Biologics in China, Takara Bio Inc. in Japan, and Samsung Biologics in South Korea are expanding their manufacturing capabilities to meet the growing demand for gene therapies. These developments are supported by government policies promoting gene therapy and collaborations with global contract development and manufacturing organizations (CDMOs).

Government initiatives aimed at supporting biotechnology innovation and improving healthcare infrastructure have catalyzed growth, with substantial funding allocated to research institutions and private sector partnerships. China, in particular, is aggressively scaling viral vector production, driven by a growing patient population, government support for biotech innovation, and a focus on becoming self-sufficient in advanced therapy manufacturing. Regulatory bodies in the region are gradually evolving, adopting more streamlined and transparent approval processes that facilitate faster clinical development and commercialization of gene therapies. The market in Asia Pacific also benefits from comparatively lower manufacturing costs and an abundant skilled workforce, which appeals to both local companies and global pharmaceutical firms seeking cost-effective production solutions.

Key Findings of Viral Vector Manufacturing Market Study:

The viral vector manufacturing market is segmented into Type, Disease Indication, Application, and End User. Based on Type, the global viral vector manufacturing market is segmented into Adenoviral Vectors, Adeno-Associated Viral Vectors, Lentiviral Vectors, Retroviral Vectors, and Others. The Adeno-Associated Viral Vectors segment held the largest share of the viral vector manufacturing market in 2024. Disease Indication is segmented into Cancer, Genetic Disorders, Infectious Disease, and Others. The Genetic Disorders segment held the largest share of the viral vector manufacturing market in 2024. By geography, the viral vector manufacturing market is segmented into North America, Asia Pacific, Europe, the Middle East & Africa, and South & Central America.

Lonza Group AG; Merck KGaA; Thermo Fisher Scientific Inc., Catalent Inc., Charles River Laboratories International Inc., WuXi AppTec Co Ltd; FUJIFILM Holdings Corp; GenScript Biotech Corporation; Takara Bio Inc., Novartis AG are among the key players profiled in the viral vector manufacturing market report. Several other major players were studied and analyzed during the viral vector manufacturing market analysis to get a holistic view of the market and its ecosystem. The viral vector manufacturing market also provides detailed market insights, which help the key players strategize their growth. The report includes growth prospects owing to the current viral vector manufacturing market trends and their foreseeable impact during the forecast period.

Contact Us
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com